- Trials with a EudraCT protocol (436)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
436 result(s) found for: Fibrillation.
Displaying page 3 of 22.
EudraCT Number: 2014-001231-36 | Sponsor Protocol Number: CV185-267(B0661025) | Start Date*: 2014-08-22 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A phase IV trial to assess the effectiveness of Apixaban compared with usual care anticoagulation in subjects with non-valvular Atrial Fibrillation undergoing cardioversion | |||||||||||||
Medical condition: Non-Valvular Atrial Fibrillation in patients undergoing Cardioversion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) BE (Completed) SE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004456-38 | Sponsor Protocol Number: XEN-D0103-CL-05 | Start Date*: 2014-04-11 | |||||||||||
Sponsor Name:Xention Limited | |||||||||||||
Full Title: A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-b... | |||||||||||||
Medical condition: Paroxysmal atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003836-35 | Sponsor Protocol Number: 2017-001-COPAF | Start Date*: 2018-08-17 | ||||||||||||||||
Sponsor Name:Population Health Research Institute | ||||||||||||||||||
Full Title: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) | ||||||||||||||||||
Medical condition: Perioperative atrial fibrillation / atrial flutter after thoracic surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-001484-79 | Sponsor Protocol Number: RIVAROXAFL3002 | Start Date*: 2013-02-06 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation | |||||||||||||
Medical condition: Prevention of stroke and non-CNS systemic embolism in patients with nonvalvular atrial fibrillation who undergo catheter ablation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001627-40 | Sponsor Protocol Number: FLE-007 | Start Date*: 2022-06-07 | |||||||||||
Sponsor Name:InCarda Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm | |||||||||||||
Medical condition: Recent-onset symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017838-44 | Sponsor Protocol Number: CJO-201 | Start Date*: 2010-04-21 | |||||||||||
Sponsor Name:Sequel Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009862-15 | Sponsor Protocol Number: D3191C00009 | Start Date*: 2009-05-25 | |||||||||||
Sponsor Name:AstraZeneca AB, European Regulatory Affairs | |||||||||||||
Full Title: A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation | |||||||||||||
Medical condition: Atrial fibrillation clinically indicated for cardioversion. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002752-20 | Sponsor Protocol Number: LAN_POAF_01 | Start Date*: 2020-12-17 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: A prospective, randomized, double- blind, placebo- controlled study to evaluate the efficacy of Landiolol hydrochloride for prevention of atrial fibrillation in patients undergoing cardiac surgery | |||||||||||||
Medical condition: Perioperative atrial fibrillation (POAF) is the most common arryhthmia after cardiac surgery with incidences ranging from 20% to 40%, depending on various patient's risk factors and the type of sur... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004327-17 | Sponsor Protocol Number: CHSY244X2201 | Start Date*: 2021-04-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, placebo-controlled, investigator- and participant-blinded study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HSY244 in participants with atrial fibrillation | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000789-22 | Sponsor Protocol Number: ARX111418 | Start Date*: 2009-05-04 | |||||||||||
Sponsor Name:GlaxoSmithKline R & D | |||||||||||||
Full Title: SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation. An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Ef... | |||||||||||||
Medical condition: Atrial fibrillation (AF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000204-13 | Sponsor Protocol Number: D1461C00006 | Start Date*: 2005-06-22 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to p... | |||||||||||||
Medical condition: Atrial fibrillation (AF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FI (Completed) SE (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005437-38 | Sponsor Protocol Number: D1250C00008 | Start Date*: 2007-03-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of... | |||||||||||||
Medical condition: Paroxysmal, persistent or permanent nonvalvular atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004847-37 | Sponsor Protocol Number: EDO-SP-01-2015 | Start Date*: 2017-10-05 | |||||||||||
Sponsor Name:FONDAZIONE G. D'ANNUNZIO, CHIETI | |||||||||||||
Full Title: A pilot study on Edoxaban for the resolution of left atrial thrombosis in patients with non-valvular atrial fibrillation | |||||||||||||
Medical condition: Non-Valvular Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000721-11 | Sponsor Protocol Number: CHPAU2019/03 | Start Date*: 2020-09-24 | ||||||||||||||||
Sponsor Name:Centre hospitalier de PAU | ||||||||||||||||||
Full Title: Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): ... | ||||||||||||||||||
Medical condition: acute coronary syndrome and atrial fibrillation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016818-24 | Sponsor Protocol Number: DRONE_C_03668 | Start Date*: 2010-08-26 | |||||||||||
Sponsor Name:sanofi aventis | |||||||||||||
Full Title: A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSi... | |||||||||||||
Medical condition: Persistant atrial fibrillation requiring conversion of AF | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) AT (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended) FI (Completed) DE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004507-13 | Sponsor Protocol Number: ANT-006 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Anthos Therapeutics | |||||||||||||
Full Title: A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with Atrial F... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002741-29 | Sponsor Protocol Number: CMAA868A2202 | Start Date*: 2018-05-15 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis bioma... | |||||||||||||
Medical condition: atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Suspended by CA) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019247-19 | Sponsor Protocol Number: DRONE_C_04629 | Start Date*: 2010-10-12 | |||||||||||
Sponsor Name:sanofi aventis groupe | |||||||||||||
Full Title: A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with pa... | |||||||||||||
Medical condition: Paroxysmal or persistent atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) FR (Completed) DE (Completed) DK (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001134-42 | Sponsor Protocol Number: GS-US-291-0102 | Start Date*: 2012-05-22 | |||||||||||
Sponsor Name:Gilead Sciences, Inc | |||||||||||||
Full Title: A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation bur... | |||||||||||||
Medical condition: Paroxysmal Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018374-20 | Sponsor Protocol Number: 6517-CL-0020 | Start Date*: 2010-12-09 | |||||||||||
Sponsor Name:Cardiome UK Limited | |||||||||||||
Full Title: A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic At... | |||||||||||||
Medical condition: Recent Onset Symptomatic Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
